These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35229082)

  • 1. Development of a hybrid alphavirus-SARS-CoV-2 pseudovirion for rapid quantification of neutralization antibodies and antiviral drugs.
    Hetrick B; Chilin LD; He S; Dabbagh D; Alem F; Narayanan A; Luchini A; Li T; Liu X; Copeland J; Pak A; Cunningham T; Liotta L; Petricoin EF; Andalibi A; Wu Y
    Cell Rep Methods; 2022 Mar; 2(3):100181. PubMed ID: 35229082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of Ha-CoV-2 Pseudovirus for Rapid Quantification of SARS-CoV-2 Variants and Neutralizing Antibodies.
    Chilin L; Hetrick B; Wu Y
    J Vis Exp; 2023 Sep; (199):. PubMed ID: 37747228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
    Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
    Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitor screening using microarray identifies the high capacity of neutralizing antibodies to Spike variants in SARS-CoV-2 infection and vaccination.
    Zhang X; Zheng M; Wang H; Zhou H; Liang T; Zhang J; Ren J; Peng H; Li S; Bian H; Wei C; Yin S; He C; Han Y; Li M; Hou X; Zhang J; Xie L; Lv J; Kan B; Wang Y; Yu X
    Theranostics; 2022; 12(6):2519-2534. PubMed ID: 35401825
    [No Abstract]   [Full Text] [Related]  

  • 6. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
    Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
    Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Affibody Molecules Specifically Bind to SARS-CoV-2 Spike Protein and Efficiently Neutralize Delta and Omicron Variants.
    Du W; Jiang P; Li Q; Wen H; Zheng M; Zhang J; Guo Y; Yang J; Feng W; Ye S; Kamara S; Jiang P; Chen J; Li W; Zhu S; Zhang L
    Microbiol Spectr; 2023 Feb; 11(1):e0356222. PubMed ID: 36511681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
    Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
    Front Immunol; 2022; 13():816389. PubMed ID: 35464418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.
    Tada T; Dcosta BM; Samanovic MI; Herati RS; Cornelius A; Zhou H; Vaill A; Kazmierski W; Mulligan MJ; Landau NR
    mBio; 2021 Jun; 12(3):e0069621. PubMed ID: 34060334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein.
    Van Ert HA; Bohan DW; Rogers K; Fili M; Rojas Chávez RA; Qing E; Han C; Dempewolf S; Hu G; Schwery N; Sevcik K; Ruggio N; Boyt D; Pentella MA; Gallagher T; Jackson JB; Merrill AE; Knudson CM; Brown GD; Maury W; Haim H
    Microbiol Spectr; 2022 Feb; 10(1):e0267621. PubMed ID: 35080430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds.
    Schöler L; Le-Trilling VTK; Eilbrecht M; Mennerich D; Anastasiou OE; Krawczyk A; Herrmann A; Dittmer U; Trilling M
    Front Immunol; 2020; 11():573526. PubMed ID: 33162987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.
    O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR
    Front Immunol; 2023; 14():1055429. PubMed ID: 36845123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern.
    Lafon E; Jäger M; Bauer A; Reindl M; Bellmann-Weiler R; Wilflingseder D; Lass-Flörl C; Posch W
    J Allergy Clin Immunol; 2022 Apr; 149(4):1242-1252.e12. PubMed ID: 35093484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions.
    Zheng Y; Larragoite ET; Williams ESCP; Lama J; Cisneros I; Delgado JC; Slev P; Rychert J; Innis EA; Coiras M; Rondina MT; Spivak AM; Planelles V
    Virol J; 2021 Jan; 18(1):1. PubMed ID: 33397387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination.
    Graninger M; Camp JV; Aberle SW; Traugott MT; Hoepler W; Puchhammer-Stöckl E; Weseslindtner L; Zoufaly A; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():888794. PubMed ID: 35711424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay.
    D'Apice L; Trovato M; Gramigna G; Colavita F; Francalancia M; Matusali G; Meschi S; Lapa D; Bettini A; Mizzoni K; Aurisicchio L; Di Caro A; Castilletti C; De Berardinis P
    Front Immunol; 2022; 13():981693. PubMed ID: 36225911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.
    Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L
    Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.